Ernest G. Hope

Ernest G. Hope (born May 24, 1966, in Hamburg, West Germany) is the chairman of the International AmeReGen Consortium of Corporations AmeReGen BioPharmaceuticals (2007 to present), and the CEO of AmeReGen-ImmunoCure SP, the robotic manufacturer of adult CITA stem cell products to treat cancer without side effects with cancer immune surveillance therapies. Hopeis known as the "Father of Adult Stem Cells" and innovator of the cancer and stem cell industry which he co-founded and helped to shape since as early as 1988. Hope is Life Member of the Academic Endowment of the German People, of the International Academy of Science and Arts, The Saudi Arabia Stem Cell Society, and also a member of the Scientific Advisory Board at the Cellular Cancer Treatment Centre Hamburg GmbH CCTC (2004 to 2011).
Hope is best known for inventing a form of cancer therapy, CITA, that rejects advanced cancers of many kinds within hours, and with autologous (i.e. patient derived, all-natural) re-built cancer immune surveillance systems. This is in contrast to the older school of poisoning cancer and the cancer patient's body with chemotherapy and cytotoxic cancer radiation therapy. Further, he is a known book author and inventor of the COURAGE method to coach cancer patients through difficult cancer management situations and to complete cancer rescue if possible. Dr Hope is a well known international speaker on T-cell immunotherapy, robotic cGMP manufacturing of stem cells and other therapeutic cell therapeutics, and on the world's first and longest experience in using adult stem cell derived T-cell immune systems to treat advanced and multi-drug resistant cancers as approved therapy in the EU, at the Cellular Cancer Treatment Centre GmbH CCTC in Hamburg. CITA, cellular intravascular targeting agents, destroy cancers based on universal flaws of its nutrient supply and vasculature. This does not cause the side effects of chemotherapy and radiation but reject cancer rapidly, so that a previously multi-drug resistant or problem cancer patient can receive a gentle rescue therapy or become a better surgical candidate than without CITA intervention. CITA can be viewed as the 5th (newest) generation of (bone marrow and) stem cell transplantation, that no longer requires the high doses or any chemo-radiation that were previously required, and that can now be applied to many solid cancers as well as blood cancers.
Education
Hope graduated in 1986 with the highest GPA of the State of Hamburg and award of the Bund der deutschen Industry. He also was noted by winning the State and National level (2nd) of the Jugend Forscht science competition '86 with an independent stem cell research entry which makes him today "The Father of Adult Stem Cells". Hope was the first to discover and publish the then unthinkable concept of "re-embryonalization of adult differentiated cells. The latter resulted in publications in Korea, Japan, and the USA.
When Hope was only 20 he was accepted directly into the PhD program of genetics and biochemistry of the Max Planck Institute in Cologne, Germany (1988). His work elucidated for the first time the relationship between human RAS cancer genes and there planned precursors, Stem Cells (Meristems), and healthy differentiation. Hope transferred to Stanford University (1991 to 1999) and completed his PhD and MD with further studies in immunology and also completed the PhD requirements for cancer biology. He also received executive training at the Stanford Graduate School of Business. Next to that, he trained at Yale University, Harvard University, the Massachusetts General Hospital & the Dana-Farber Cancer Institute.
Hope has been mentored by Linus Pauling PhD double Nobel laureate winner and worked at Stanford as the assistant of Nobel laureate Paul Berg PhD.
Hope is a recipient of the Max-Planck/Weitzman Institute MINERVA Scholarship and Scientific Exchange Award, the US National Institute of Health Scholarship, and the Stanford Medical Center's Award for Excellence in Teaching.
Career
Ernest Hope is currently the Chairman of AmeReGen BioPharmaceuticals INC. SPC. Hope is the former chief executive officer of ImmunoCure Corp (2000 to 2007) and the former CEO and Chairman of the Board for Ladera BioTech Corporation of Ladera, California. Hope was also US Marketing Director of ZYMED Biopharmaceuticals & Diagnostics, INC. (2003) and was House Staff Physician of Internal Medicine at Duke University Medical Center (2000).
Personal life
His father is Dr. med. Ulrich Hoppe and mother is Helga. His brother Hans became Rhodes Scholar in '86, and today is lecturer in biochemistry and immunology at Christ College of Oxford University, England.

Main Menu

See Also

Main Menu